Disease Markers / 2019 / Article / Tab 5

Research Article

sFlt-1/PlGF Ratio as a Predictive Marker in Women with Suspected Preeclampsia: An Economic Evaluation from a Swiss Perspective

Table 5

Budget impact analysis for the no-test and test (sFlt-1/PlGF) strategies.

YearNo-test strategyTest strategyTotal cost for entire cohort (€)Difference in costs (no-test strategy vs. test strategy; €)
Costs (€) [19]Costs (€)Test/no-test strategyNo-test strategy

1486753,173,304121712,874,72866,048,03266,469,362–421,330
2348438,063,651260027,505,58163,351,91564,221,605–869,690
3243426,592,115365038,613,60460,870,23762,049,860–1,179,623
4108411,842,996500052,895,34958,390,27759,951,556–1,561,278
50608464,363,06056,088,68857,924,209–1,835,520
Total within 5 years11,869129,672,06618,551196,252,323304,749,152310,616,592–5,867,441

PlGF: placental growth factor; sFlt-1: soluble fms-like tyrosine kinase-1.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.